By Stephen Nakrosis

Pfizer Inc. (PFE) said Thursday the U.S. Food and Drug Administration approved Xeljanz extended-release tablets for adult patients with moderately to severely active ulcerative colitis.

Pfizer said its extended-release 11 mg and 22 mg tablets of Xeljanz, or tofacitinib, was indicated "for the once-daily treatment of adult patients with moderately to severely active ulcerative colitis, after an inadequate response or intolerance to TNF blockers."

Xeljanz is also indicated for the treatment of Rheumatoid Arthritis and Psoriatic Arthritis, the company said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 12, 2019 18:28 ET (23:28 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos Pfizer.
Pfizer (NYSE:PFE)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos Pfizer.